Yokota et al., 1989 - Google Patents
The prevalence of antibody to p42 of HTLV‐1 among ATLL patients in comparison with healthy carriers in JapanYokota et al., 1989
- Document ID
- 16376934245000102143
- Author
- Yokota T
- Cho M
- Tachibana N
- McLane M
- Takatsuki K
- Lee T
- Mueller N
- Essex M
- Publication year
- Publication venue
- International journal of cancer
External Links
Snippet
A gene product (p42) of the long open reading frame, now termed tax, of the viral genome of human T‐cell leukemia virus type 1 (HTLV‐1) may be related to the transformation of T cells in adult T‐cell leukemia‐lymphoma (ATLL). To evaluate its association with the disease, we …
- 102000004965 antibodies 0 title abstract description 89
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from micro-organisms
- Y10S530/826—Viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1194794A (en) | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | |
| Yoshida et al. | Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. | |
| Watanabe et al. | Sequence homoiogy of the simian retrovirus genome with human t-cell leukemia virus type I | |
| Lipka et al. | Segregation of human T cell lymphotropic virus type I and II infections by antibody reactivity to unique viral epitopes | |
| Robert-Guroff et al. | Evidence for human T cell lymphoma-leukemia virus infection of family members of human T cell lymphoma-leukemia virus positive T cell leukemia-lymphoma patients. | |
| JP2851278B2 (en) | Antigen for detecting antibody against HTLV-I, peptide composition as vaccine for ATL, and method using the same | |
| EP0196319B1 (en) | Retroviral polypeptides associated with human cellular transformation | |
| Strand et al. | Structural proteins of mammalian oncogenic RNA viruses: immunological characterization of the p15 polypeptide of Rauscher murine virus | |
| US20020042045A1 (en) | METHODS FOR THE DETECTION OF HTLV-II ANTIBODIES EMPLOYIING NOVEL HTLV-II nra ENVELOPE PEPTIDES | |
| Yokota et al. | The prevalence of antibody to p42 of HTLV‐1 among ATLL patients in comparison with healthy carriers in Japan | |
| US6531574B1 (en) | T-lymphotrophic virus | |
| Robert-Guroff et al. | Identification of HTLV p19 specific natural human antibodies by competition with monoclonal antibody | |
| Thorley-Lawson | Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells | |
| JP3271666B2 (en) | Discrimination between antibodies against HTLV-I, HTLV-II or related retrovirus, detection of novel peptides, antibodies and immunoassay kit | |
| Reitz Jr et al. | Relatedness by nucleic acid hybridization of new isolates of human T-cellleukemia-lymphoma virus (HTLV) and demonstration of provirus in uncultured leukemic blood cells | |
| Lal et al. | Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy | |
| Yamamoto et al. | Experimental infection of cynomolgus monkeys with a human retrovirus, adult T-cell leukemia virus | |
| JP2643598B2 (en) | Synthetic peptide composition having immunoreactivity to HTLV-I antibody | |
| EP0439077B1 (en) | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV | |
| Becker, WB,* Becker, MLB,* Homma, T.,** Brede, HD*** & Kurth | Serum antibodies to human T-cell leukaemia virus type I in different ethnic groups and in non-human primates in South Africa | |
| Palker et al. | C-terminal region of human T cell lymphotropic virus type I (HTLVI) p19 core protein is immunogenic in humans and contains an HTLVI-specific epitope. | |
| AU641554B2 (en) | Novel peptide antigens and immunoassays, test kits and vaccines using the same | |
| US5378805A (en) | Immunoreactive HTLV-I/II ENV and POL peptides | |
| Nakamura et al. | Elevated antibodies to synthetic peptides of HTLV-1 envelope transmembrane glycoproteins in patients with HAM/TSP | |
| Lal et al. | Isotypic and IgG subclass restriction of the humoral immune responses to human T-lymphotropic virus type-I |